ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Premium Icon프리미엄 Help Menu
S&P 500
5,982.72
-0.84%
US Tech 100
21,112.40
-1.21%
다우존스 지수
42,215.80
-0.70%
Bitcoin
105,507.82
0.87%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) 뉴스

argenx SE

argenx SE (ARGX)

Argen X SE
540.71
-10.51
(-1.91%)
마감 18 6월 5:00AM
15분 지연 - 실시간으로 업그레이드
541.85
1.14
(0.21%)
시간외 거래: 8:55AM
15분 지연 - 실시간으로 업그레이드

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

ARGX 뉴스

공식 뉴스 전용

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
11 6월 2025
ARGX (-1.91%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
08 5월 2025
ARGX (-1.91%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
28 4월 2025
ARGX (-1.91%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
08 4월 2025
ARGX (-1.91%)

ARGX Discussion

게시물 보기
Monksdream Monksdream 7 월 전
ARGX new 52+week high
👍️0
Monksdream Monksdream 9 월 전
ARGX over $500

👍️0
Monksdream Monksdream 10 월 전
ARGX new 52 week high
👍️0
Monksdream Monksdream 11 월 전
ARGX under $500
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 4 년 전
Looking good
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 4 년 전
Progress in Sub-cu Efgartigimod was discussed in some detail yesterday during the Halozyme conference call.
👍️0
jonny_red jonny_red 6 년 전
3 Penny Stocks To Buy Or Sell Before Friday? 1 Up 110% This Quarter

$CLSD $AR $AGRX

https://www.transparenttraders.me/2019/11/3-penny-stocks-to-buy-or-sell-before.html
👍️0
ClayTrader ClayTrader 7 년 전
* * $AGRX Video Chart 11-01-18 * *

Link to Video - click here to watch the technical chart video

👍️0
riche riche 7 년 전
Efgartigimod is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G, or IgG, antibodies for which few innovative biologic treatments have been approved and severe unmet medical need exists. Efgartigimod has been created to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications: multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus, myasthenia gravis and skin blistering

👍️0
riche riche 7 년 전
Year targets !!

KBC 87 euro Wedbush 121 $ = 104 euro Piper Jaffray 154 $ = 132 euro JMP Securities 150 $ = 129 euro Stiffel 139 $ = 119,50 euro Nomura 161 $ = 138,40 Kempen en Co 140 euro

STRONG BUY !!!
👍️0
riche riche 7 년 전
1-4 Dec 2018: Efgartigimod full Phase II ITP data, ARGX-110 full Phase I AML dose-escalation data, ARGX-110 full Phase II CTCL data YE 2018: launch of Phase III MG trial with Efgartigimod.

👍️0
riche riche 7 년 전
https://thefly.com/landingPageNews.php?id=2794139 Argenx data concerns over rescue therapy unfounded, says Piper Jaffray Argenx last week reported positive Phase II immune thrombocytopenia data on efgartigimod showing clean safety and clear efficacy, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. He points out that twelve, or 46%, efgartigimod-treated patients achieved clinically meaningful platelet improvement. The analyst views concern over rescue therapy and bleeding events as unfounded and reiterates an Overweight rating on Argenx shares with a $154 price target. Bioscience liked last!Lampi, Bioscience waardeerde(-n)

👍️0
riche riche 7 년 전
Sorry, theWhat a JOKE!...SOLD 3.5M shares at $86.50 a share...BUT...also gave each share an option to buy a share at equivalent of $ .15 a share.... therefore 7MM shares at equivalent $43.25 a share...THIS IS GOING DOWN!!! "closing of its public offering in the United States and an offering in Europe only to qualified investors (within the meaning of Directive 2003/71/EC, as amended) (the Offering) of 3,475,000 American Depositary Shares (ADSs) at a price to the public of $86.50 per ADS, for gross proceeds of approximately $300.6 million, before deducting underwriting discounts and commissions and offering expenses payable by argenx.Each of the ADSs offered represents the right to receive one ordinary share, nominal value of #$%$0.10 per share. All of the ADSs in the Offering were offered by argenx." Ik heb de vraag gisterenavond voor gelegd bij ARgen-X Hieronder het bericht zoals het uitgelegd moet worden . Gegeven door niet minder dan Joke Comijn dir . IR ARgenx Dag Bioscience De nominale waarde is de waarde van het aandeel zoals die staat beschreven in de statuten van een NV. De nominale waarde heeft niets te maken met de werkelijke waarde van een aandeel, en ook niet met de discount van de transactie. Dit is duidelijk te zien op de balans van de meeste (beursgenoteerde) bedrijven waar je onder de equity zowel share capital (de nominale waarde van alle aandelen) als share premium (de betaalde waarde voor de aandelen bovenop de nominale waarde) terugvindt. https://nl.wikipedia.org/wiki/Nominale_waarde Bijkomend wil ik nog laten weten dat de inschrijvers op ADSen geen recht hebben op een ‘bijkomend’ aandeel: bij de kapitaalverhoging zijn de aandelen gecreëerd, die vervolgens in bewaring zijn gegeven, die op haar beurt per in bewaring gegeven aandeel een certificaat (American Depository Security) heeft uitgegeven aan de aandeelhouders die hun argenx aandelen op Nasdaq verhandelen. De reden hiervoor is dat er juridische belemmeringen zijn om aandelen van een Nederlandse vennootschap rechtstreeks op Nasdaq te verhandelen. Met vriendelijke groeten, Joke DUS de aandelen zijn gekocht voor $ 86,50 en niet voor minder !!! ( geen extra korting . Daar zitten we nu dus al 11 $ onder .

Lees meer op: https://beursig.com/forum/viewtopic.php?f=4&t=1804&start=2050 voor meer informatie answer is in Dutch.
👍️0
riche riche 7 년 전
https://clinicaltrials.gov/ct2/show/NCT03102593
👍️0
Justfactsmam Justfactsmam 7 년 전
I don't think so...TOXIC FINANCING DEAL ....EU private financing deal...just gave away 7MM share at $43.50 a share when was trading over double that last week...

3.5 MM shares sold at $86.50 a share...BUT...also gave each share an option to buy a share at equivalent of $ .15 a share.... therefore 7MM shares at equivalent $43.25 a share...

THIS IS GOING DOWN!!!
👍️0
stocktrademan stocktrademan 7 년 전
ARGX buy 75.10



















normal chart




log chart



👍️0

최근 히스토리

NASDAQ
ARGX
argenx
Delayed Upgrade Clock
ADVFN Logo
대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN Ltd - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지